Critical Analysis: LabCorp

Critical Analysis: LabCorp

LabCorp and CareDx are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. LabCorp presently has a consensus price target of $190.47, suggesting a potential upside of 8.09%.

from Biotech News

Комментариев нет:

Отправить комментарий

Pharmacy News Digest

Архив блога